EMA Policy 0070 External Guidance Update

Even though the European Medicines Agency (EMA) has suspended publication of clinical data through Policy 0070 due to its Brexit business continuity plan, EMA posted a Policy 0070 external guidance update on November 11, 2018. Revision 4 is now in effect. Policy 0070 External Guidance Update - Major Changes Several major changes are noted in this “Summary of Changes” document, including: Cl ...

Read More

Synchrocast Ep 3: FDA Scrutiny Around ENDS Products

Synchrogenix's Darshan Kulkarni, Vice President, Regulatory Strategy and Policy, and Evan Richardson, Director, Regulatory Services talk about the recent FDA scrutiny around electronic nicotine delivery system (ENDS) products in this episode of Synchrocast. Evan oversees our work preparing regulatory submissions to the Center for Tobacco Products. Listen to learn more about how the FDA is attempti ...

Read More

Synchrocast Ep 2: Narrative Writing Challenges and Approach

Synchrogenix's Tatyana Wanderer, Executive Director of Services Operations and Kelly Danyow, Associate Director of Workstream Leads have a combined 15 years of experience leading narrative projects. Listen as they discuss clients' patient narrative writing challenges and needs, and Synchrogenix's integrated and streamlined approach to narrative writing. Listen to the Synchrocast Download t ...

Read More

7 Things to Know About the China Pharmaceutical Industry

China is the second largest pharmaceutical market in the world. Demand is likely to increase as the government introduces reforms to improve the country’s health care system. These changes are helping multinational drug makers tap into the Chinese pharmaceutical market. Synchrogenix’s China Service Line has compiled a list of seven things to know about the China pharmaceutical industry to help you ...

Read More

Implications of FDA’s Decision to Issue Fines for Failing to Submit Clinical Trial Data

The U.S. Food and Drug Administration (FDA) issued a draft guidance last week proposing levying heavy fines on pharmaceutical companies and contract research organizations (CROs) that do not post clinical trial results online. FDA said in the draft guidance, titled “Civil Money Penalties Relating to the ClinicalTrials.gov Data Bank,” that failure to register trials or submit results to ClinicalTri ...

Read More
1 2 3